Literature DB >> 24438064

Time to begin adjuvant chemotherapy and survival in breast cancer patients: a retrospective observational study using latent class analysis.

Amy Downing1, Christopher Twelves, David Forman, Gill Lawrence, Mark S Gilthorpe.   

Abstract

The analysis of time to treatment data and the evaluation of subsequent effects on health outcomes can be complex due to the nature of the data and the relationships amongst the variables. This study proposes an alternative method of analyzing such data using latent class analysis (LCA). The association between time to begin adjuvant chemotherapy after breast cancer surgery and survival was investigated using both "traditional" regression analysis and LCA. Women with breast cancer undergoing surgery and subsequent adjuvant chemotherapy in two English regions between January 01, 1998 and December 31, 2004 were identified from a linked cancer registry-Hospital Episode Statistics dataset (n = 10,366). Patient, tumor, and treatment information were extracted. A Cox proportional hazards model was used to analyze 5-year survival using regression analysis and LCA. Using "traditional" regression analysis, women beginning chemotherapy >10 weeks after surgery had worse survival in region 1 (HR = 1.49, 95% CI 1.13-1.95 compared to <3 weeks) but not region 2. LCA split the women into three groups representing short, medium, and long waits. The median time to begin chemotherapy in the "long" wait group was 70 (region 1) and 57 (region 2) days. In this group, increased time to begin chemotherapy was associated with worse survival (region 1 HR = 1.15, 95% CI 1.11-1.18; region 2 HR = 1.08, 95% CI 1.03-1.13 per week increase). LCA identified a group of 13-15% of women for whom a longer time to begin chemotherapy had an adverse effect on survival. This methodology provides an excellent framework in which to examine complex associations between the delivery of patient care and patient outcomes.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  breast cancer; chemotherapy; latent class analysis; survival; time to treatment

Mesh:

Year:  2013        PMID: 24438064     DOI: 10.1111/tbj.12209

Source DB:  PubMed          Journal:  Breast J        ISSN: 1075-122X            Impact factor:   2.431


  6 in total

1.  Time to Completion of Breast Cancer Treatment and Survival.

Authors:  Debra Pratt; Talia Burneikis; Chao Tu; Stephen Grobmyer
Journal:  Ann Surg Oncol       Date:  2021-06-08       Impact factor: 5.344

2.  The association of delay in curative intent treatment with survival among breast cancer patients: findings from the Women's Health Initiative.

Authors:  Rachel Yung; Roberta M Ray; Joshua Roth; Lisa Johnson; Greg Warnick; Garnet L Anderson; Candyce H Kroenke; Rowan T Chlebowski; Michael S Simon; Chunkit Fung; Kathy Pan; Di Wang; Wendy E Barrington; Kerryn W Reding
Journal:  Breast Cancer Res Treat       Date:  2020-02-15       Impact factor: 4.872

3.  Access to Care in Vermont: Factors Linked With Time to Chemotherapy for Women With Breast Cancer-A Retrospective Cohort Study.

Authors:  Ali Johnson; Leanne Shulman; Jennifer Kachajian; Brian L Sprague; Farrah Khan; Ted James; David Cranmer; Peter Young; Ruth Heimann
Journal:  J Oncol Pract       Date:  2016-08-30       Impact factor: 3.840

4.  Association between initiation of adjuvant chemotherapy beyond 30 days after surgery and overall survival among patients with triple-negative breast cancer.

Authors:  Erik Heeg; Perla J Marang-van de Mheen; Marissa C Van Maaren; Kay Schreuder; Rob A E M Tollenaar; Sabine Siesling; Monique E M M Bos; Marie-Jeanne T F D Vrancken Peeters
Journal:  Int J Cancer       Date:  2019-11-28       Impact factor: 7.396

5.  Prolonged Time to Adjuvant Chemotherapy Initiation Was Associated with Worse Disease Outcome in Triple Negative Breast Cancer Patients.

Authors:  Lifen Cai; Yiwei Tong; Xiaoping Zhu; Kunwei Shen; Juanying Zhu; Xiaosong Chen
Journal:  Sci Rep       Date:  2020-04-27       Impact factor: 4.379

6.  Survival and time to initiation of adjuvant chemotherapy among breast cancer patients: a systematic review and meta-analysis.

Authors:  Qiao-Hui Zhan; Jian-Qin Fu; Fang-Meng Fu; Jie Zhang; Chuan Wang
Journal:  Oncotarget       Date:  2017-12-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.